Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 5Breast Neoplasms 4Uterine Cervical Neoplasms 3Ovarian Neoplasms 3Head and Neck Neoplasms 3Endometrial Neoplasms 3Neoplasms by Site 2Neoplasms 2Hereditary Sensory and Autonomic Neuropathies 2Breast Diseases 2Salivary Gland Neoplasms 1Esophageal Squamous Cell Carcinoma 1

Interventions

pembrolizumab 7Nivolumab 4Carboplatin 4Cisplatin 3spartalizumab 2regorafenib 2durvalumab 2Paclitaxel 2Itraconazole 2Immune Checkpoint Inhibitors 2Gemcitabine 2Fluorouracil 2130-nm albumin-bound paclitaxel 2tremelimumab 1toripalimab 1ribociclib 1osimertinib 1obinutuzumab 1nazartinib 1naptumomab estafenatox 1liposomal doxorubicin 1enzalutamide 1elgemtumab 1aflibercept 1abiraterone 1SGN-LIV1A 1Ritonavir 1Remote Patient Monitoring 1Oxaliplatin 1ON 01910 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × Fulvestrant × Head & Neck × Clear all
NCT07109726 2026-05-22

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Terremoto Biosciences Inc.

Phase 1/2 Recruiting
205 enrolled
BreastGastrointestinalGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡